Literature DB >> 27880077

Teriparatide Treatment in Elderly Patients With Sacral Insufficiency Fracture.

Jun-Il Yoo1, Yong-Chan Ha1, Hyun-Jun Ryu1, Geun-Wu Chang1, Young-Kyun Lee2, Moon-Jib Yoo3, Kyung-Hoi Koo2.   

Abstract

Context and Objective: Pain-related immobility because of insufficiency fractures may result in serious complications and a high mortality rate in senile patients with preexisting comorbidities. This study aimed to evaluate the efficacy of teriparatide in patients with sacral insufficiency fractures. Design, Setting, and Participants: This retrospective, case-controlled, single center study, performed from 2009 to 2014, included 41 patients who underwent radiographs, magnetic resonance imaging, and/or bone scans to document sacral insufficiency fractures. Intervention: The intervention involved teriparatide at a once-daily subcutaneous dose of 20 μg within 2 days of hospital admission (21 patients). Twenty patients (control group) did not receive teriparatide. Main Outcome Measures: Functional outcome was assessed using a visual analog scale for pain and the time to mobilization. Pelvic anteroposterior radiographs were repeated at 0, 1, 4, 8, 12, and 16 weeks until radiographic evidence of cortical bridging at the fracture site was confirmed.
Results: From the date of admission to 4 weeks, the mean visual analog scale score improved between the 2 groups. The mean time to mobilization was 1.2 ± 0.4 weeks in patients who received teriparatide treatment, compared with 2.0 ± 0.3 weeks in controls (P < 0.001). At 8 weeks, all fractures in the teriparatide treatment group and 4 fractures in the control group had healed. Conclusions: In senile patients with preexisting comorbidities who have sacral insufficiency fractures, teriparatide treatment may achieve earlier pain reduction and mobilization and reduce healing time.
Copyright © 2017 by the Endocrine Society

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27880077     DOI: 10.1210/jc.2016-3582

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  [Clinical outcome and revenue situation after conservative, interventional and surgical/osteosynthetic treatment of sacral insufficiency fractures].

Authors:  Julian Ramin Andresen; Axel Prokop; Mathias Wollny; Sebastian Radmer; Hans-Christof Schober; Reimer Andresen
Journal:  Unfallchirurg       Date:  2020-12-10       Impact factor: 1.000

2.  Role of Supplemental Teriparatide Therapy to Augment Functional and Radiological Outcomes in Osteoporotic Intertrochanteric Hip Fractures in the Elderly Population.

Authors:  Sanket Mishra; Deepankar Satapathy; Sidhartha Samal; Nego Zion; Udeepto Lodh
Journal:  Cureus       Date:  2022-06-22

Review 3.  Sacral Insufficiency Fractures: a Review of Risk Factors, Clinical Presentation, and Management.

Authors:  Ivan Urits; Vwaire Orhurhu; Jessica Callan; Nishita V Maganty; Sara Pousti; Thomas Simopoulos; Cyrus Yazdi; Rachel J Kaye; Lauren K Eng; Alan D Kaye; Laxmaiah Manchikanti; Omar Viswanath
Journal:  Curr Pain Headache Rep       Date:  2020-02-17

4.  Effect of weekly teriparatide injections on osteoporotic fracture healing: protocol for a double-blind, randomised controlled trial.

Authors:  Junxiong Zhu; Chenggui Zhang; Jialin Jia; Wanqiong Yuan; Min Zhang; Huijie Leng; Chunli Song
Journal:  BMJ Open       Date:  2021-04-01       Impact factor: 2.692

Review 5.  Fragility Fractures of the Pelvis and Sacrum: Current Trends in Literature.

Authors:  Erick Heiman; Pasquale Gencarelli; Alex Tang; John M Yingling; Frank A Liporace; Richard S Yoon
Journal:  Hip Pelvis       Date:  2022-06-07

6.  Teriparatide Associated with Fewer Refractures and Higher Body Heights of Cemented Vertebrae after Vertebroplasty: A Matched Cohort Study.

Authors:  Yi-Shan Yang; Yi-Syue Tsou; Wen-Cheng Lo; Yung-Hsiao Chiang; Jiann-Her Lin
Journal:  Sci Rep       Date:  2020-04-07       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.